Catalog No.
Product Name
Application
Product Information
Citations
-
CXCR4 Antagonist
CXCR4 Antagonist 4 is a potent antagonist of the CXCR4 receptor, exhibiting an IC50 of 24 nM. It demonstrates enhanced permeability as assessed by PAMPA and has reduced activity on CYP 2D6. This compound is particularly effective in inhibiting the entry of human immunodeficiency virus, with an IC50 value of 7 nM, making it a valuable tool for research in virology and therapeutic development targeting CXCR4-mediated pathways. -
CXCR Antagonist
GSK812397 is a potent CXCR4 antagonist that functions by inhibiting the CXC chemokine receptor 4, a critical co-receptor for HIV-1 entry into host cells. This compound has demonstrated significant biological activity, making it a promising candidate for HIV treatment research. Its ability to suppress the replication of various late cytopathic viruses marks GSK812397 as a valuable reagent in the development of innovative anti-HIV therapies. Additionally, scalable synthetic routes enable efficient production, ensuring sufficient quantities for comprehensive investigation. -
CXCR Antagonist
CXCR4 antagonist 1 is a selective antagonist of the chemokine receptor CXCR4. It exhibits significant anti-HIV activity by inhibiting the interaction of CXCR4 with its ligands, thereby blocking viral entry into host cells. This compound is valuable in research focused on HIV pathogenesis and the development of therapeutic strategies targeting CXCR4. -
CCR5 Inhibitor
CMPD167 is a selective CCR5 inhibitor that exerts its antiviral effects by blocking the CCR5 receptor, which is critical for the entry of certain viruses into host cells. This compound demonstrates potent antiviral activity in vitro, making it a valuable tool for research on viral infections, particularly in studies related to HIV. CMPD167 can facilitate investigations into CCR5-related pathways and the development of therapeutic strategies targeting viral entry mechanisms. -
CXCR4 Antagonist
HF50731 is a potent antagonist of CXCR4, demonstrating a binding affinity with an IC50 value of 19.8 nM. This compound effectively inhibits key biological processes such as calcium mobilization and cell migration, with IC50 values of 119.2 nM and 621.4 nM, respectively. Additionally, HF50731 demonstrates the ability to inhibit HIV-1 infection through CXCR4 coreceptor blockade, achieving an IC50 of 1.5 μM. HF50731 is valuable for research in immunology, virology, and cancer biology focused on CXCR4 signaling pathways. -
CCR5 inhibitor
CB-0821 is a high-affinity CCR5 inhibitor with a Ki value of 0.04 nM. It effectively binds to the hydrophobic pocket of the CCR5 protein, disrupting the interactions between viral proteins and CCR5, which inhibits viral entry into cells. This compound is poised for use in anti-HIV research applications, facilitating studies on viral tropism and potential therapeutic strategies. -
CXCR Inhibitor
AMD-3329 is a selective CXCR4 inhibitor that targets the chemokine receptor involved in HIV-1 and HIV-2 entry into host cells. By obstructing CXCR4, AMD-3329 effectively inhibits viral replication, making it a valuable tool in HIV research. This compound is suitable for studies focused on developing therapeutic strategies against X4-tropic HIV strains and understanding the mechanisms of viral entry and infection. -
CCR5 Antagonist
E913 is a selective antagonist of the CCR5 receptor, effectively inhibiting the binding of macrophage inflammatory protein-1alpha (MIP-1alpha) to CCR5 with an IC50 of 0.002 μM. This compound also blocks MIP-1alpha-induced cellular Ca2+ mobilization, demonstrating an IC50 of 0.02 μM. E913 significantly suppresses the replication of both laboratory and primary R5 HIV-1 strains, including multidrug-resistant variants, with IC50 values ranging from 0.03 to 0.06 μM. This reagent is valuable for research into HIV-1 infection and related mechanisms of immune response. -
CCR5 Antagonist
GSK-214096 is a selective CCR5 antagonist that inhibits HIV-1 entry through the blockade of the virus's glycoprotein 120 (gp120). By targeting the CCR5 co-receptor, this compound plays a critical role in interrupting HIV-1 infection pathways. It is valuable for research applications focused on HIV-1 biology and therapeutic discovery. -
HIV Inhibitor
KRH-3955 is a potent CXCR4 antagonist that demonstrates significant anti-HIV-1 activity, particularly against X4 strains. It effectively inhibits the replication of various X4 HIV-1 clinical isolates and is active against recombinant strains with resistance mutations in reverse transcriptase, protease, and tyrosinase. KRH-3955 disrupts the binding of SDF-1alpha to CXCR4, thereby interfering with calcium signaling through this receptor, along with inhibiting antibody binding to CXCR4. With an oral bioavailability of 25.6% in rats, KRH-3955 has shown efficacy in vivo, making it a valuable tool for HIV research. -
Anti-inflammatory/Hemostatic Agent
Ethyl 10-bromodecanoate is an anti-inflammatory and hemostatic agent that targets pathways involved in inflammation and blood coagulation. It is structurally related to linolenic acid and exhibits notable antibacterial properties, making it a valuable compound for research into inflammatory responses and hemostasis. This reagent is suitable for studies focused on elucidating the molecular mechanisms of anti-inflammatory effects and potential therapeutic applications in hemostatic disorders. -
TLR8 Agonist
TLR8 Agonist 4 is a potent agonist targeting Toll-like receptor 8 (TLR8), demonstrating efficacy against both wild-type and drug-resistant HBV strains, including those resistant to lamivudine and entecavir. The compound exhibits IC50 values of 0.15 μM and 0.10 μM, respectively, highlighting its potential for use in antiviral research and therapeutic development against Hepatitis B virus. -
HBsAg Peptide
HBV Seq2 aa:28-39 is a peptide derived from Hepatitis B Surface Antigen (HBsAg) that specifically interacts with major histocompatibility complex (MHC) class I molecules. This interaction is crucial for the activation of CD8+ T cells, making it an important tool for studying immune responses to HBV infection. It is widely used in vaccine research and T cell epitope mapping to enhance understanding of viral pathogenesis and immune evasion mechanisms. -
HCV Inhibitor
ASP5286 is a novel non-immunosuppressive inhibitor targeting cyclophilin, primarily designed for research applications related to Hepatitis C virus (HCV). This compound demonstrates potent antiviral activity, making it a valuable tool for investigating HCV replication and pathogenesis. Researchers can utilize ASP5286 in studies focused on the mechanisms of viral infection and the development of therapeutic strategies against HCV. -
Cyclophilin/HCV Inhibitor
SMCypI C31 is a non-peptidic inhibitor of cyclophilin with significant peptidyl-prolyl cis/trans isomerase (PPIase) inhibitory activity, demonstrating an IC50 of 0.1 µM. This compound exhibits broad-spectrum antiviral efficacy against various HCV genotypes, including 1a, 1b, 2a, 3a, and 5a, with EC50 values ranging from 1.20 to 7.76 μM in subgenomic replicon assays. SMCypI C31 targets and disrupts the interaction between cyclophilin A and NS5A, making it a valuable tool for research into HCV therapies. -
Cyclophilin A Inhibitor
Cyclophilin Inhibitor 3 is a selective inhibitor of Cyclophilin A, demonstrating significant antiviral activity against Hepatitis C Virus (HCV) with an EC50 of 4.2 μM. This compound is essential for studies investigating the role of CypA in viral replication and may serve as a valuable tool for antiviral research and therapeutic development targeting HCV infections. -
Anti-inflammatory Agent
1-Terpineol is a lipid-soluble monoterpenoid alcohol recognized for its anti-inflammatory properties. This compound exhibits significant antibacterial and antioxidant activities, making it valuable for various research applications. It is commonly explored in studies related to inflammation and oxidative stress management. -
Antimicrobial and Anti-inflammatory Agent
1-Hydroxy-2-methylanthraquinone targets various biological pathways as an antimicrobial and anti-inflammatory agent. This compound demonstrates significant antimicrobial and antioxidant properties, making it useful for studies related to infection control and inflammation modulation. Its pesticidal activity further broadens its applicability in agricultural research and product development. -
Anti-inflammatory Agent
Anti-inflammatory agent 14, also known as compound 28, is a potent anti-inflammatory compound that inhibits inflammation-related pathways. It exhibits a minimum inhibitory concentration (MIC50) of 2 μM against Mycobacterium tuberculosis strain H37Rv, demonstrating significant antibacterial properties. This reagent is valuable for research applications focused on anti-inflammatory therapies and tuberculosis studies. -
Anti-inflammatory Agent
2-Methyldecalin is a chemical compound known for its anti-inflammatory properties. It exhibits significant antioxidant and antibacterial activities, making it a valuable reagent for studies related to inflammatory conditions. This compound is suitable for various research applications aimed at understanding and mitigating inflammation-related disorders. -
CcrM Inhibitor
NSC177365 is a potent CcrM inhibitor that acts by competitively disrupting DNA binding. It demonstrates significant antibacterial activity, displaying IC50 values of 2.3 μM and 14.6 μM against C. crescentus and M. lincolnii, respectively. Furthermore, NSC177365 has potential applications in reversing neurodegenerative disorders and shows promise as an anticancer agent, making it a valuable tool for chemical research. -
Anti-inflammatory Agent
Vasicinolone is a natural alkaloid that functions primarily as an anti-inflammatory agent. It demonstrates significant anti-inflammatory and antimicrobial activity, making it valuable for research applications related to inflammation and infection. Its potential use in therapeutic development highlights its importance in the study of chronic inflammatory conditions. -
Anti-inflammatory Agent
Anti-inflammatory agent 94 (compound 4b) is a potent cannabinoid ligand targeting the CB1 and CB2 receptors, exhibiting Kis of 29 nM and 8 nM, respectively. This compound demonstrates significant anti-inflammatory activity, making it a valuable tool for studying inflammation-related processes. Its application in research may enhance understanding of cannabinoid signaling and its therapeutic potential in inflammatory conditions. -
CCR6 Antagonist
CCR6 antagonist 1 is a selective antagonist of the CCR6 receptor, effectively inhibiting the CCL20/CCR6 signaling pathway. This compound is instrumental in research focusing on autoimmune-mediated inflammatory diseases, particularly inflammatory bowel diseases (IBDs). Its role in modulating the CCR6 axis provides insights into potential therapeutic strategies for managing such conditions. -
CCR Antagonist
Abaucin is a potent CCR2 antagonist, demonstrating an IC50 of 360 nM. It selectively inhibits CCR2 without affecting CCR1, making it a valuable tool for studying immunological responses and inflammatory processes. Abaucin is applicable in research focusing on the role of CCR2 in disease models and therapeutic interventions targeting chemokine receptors. -
CCR Inhibitor
CCR6 Inhibitor 1 is a highly selective inhibitor of the CCR6 receptor, demonstrating IC50 values of 0.45 nM for monkey CCR6 and 6 nM for human CCR6, while exhibiting minimal activity against human CCR1 and CCR7. This inhibitor effectively prevents ERK phosphorylation, making it a valuable tool in the study of signaling pathways. CCR6 Inhibitor 1 is employed in research focused on autoimmune diseases and cancer, facilitating insights into therapeutic strategies targeting CCR6-related pathways. -
CCR7 Antagonist
CCR7 Ligand 1 is a potent allosteric antagonist targeting the human CC chemokine receptor 7 (CCR7), with a dissociation constant (Kd) of 3 nM. This thiadiazole-dioxide compound effectively inhibits arrestin binding upon CCL19 activation, exhibiting an IC50 of 7.3 μM. CCR7 Ligand 1 is valuable for research applications focused on immune response modulation, chemokine signaling pathways, and therapeutic development for related conditions. -
CCR4 Inhibitor
Zelnecirnon is an orally active CCR4 inhibitor that effectively blocks the recruitment of Th2 inflammatory immune cells to inflamed tissues. This compound exhibits potent anti-inflammatory activity, making it valuable in researching allergic inflammation associated with conditions such as atopic dermatitis and asthma. Zelnecirnon serves as a critical tool for understanding and developing therapeutic strategies in inflammatory diseases. -
CCR1 Antagonist
J-113863 is a potent and selective antagonist of the CCR1 receptor, demonstrating IC50 values of 0.9 nM and 5.8 nM for human and mouse CCR1, respectively. Additionally, it acts as a strong antagonist of the human CCR3 receptor (IC50 of 0.58 nM), while exhibiting weak antagonistic activity against mouse CCR3 (IC50 of 460 nM). J-113863 shows inactivity toward CCR2, CCR4, and CCR5, as well as LTB4 and TNF-α receptors. This compound is primarily utilized in anti-inflammatory research applications. -
CCR4 Antagonist
C-021 dihydrochloride is a highly effective antagonist of the CC chemokine receptor-4 (CCR4). It significantly inhibits chemotaxis in both human and mouse models, exhibiting IC50 values of 140 nM and 39 nM, respectively. Additionally, C-021 dihydrochloride demonstrates capability in preventing the binding of human CCL22-derived [35S]GTPγS to CCR4, with an IC50 of 18 nM. This compound is valuable for research applications focused on immune response modulation and related therapeutic strategies. -
CCR6 Antagonist
PF-07054894 is a potent and orally active antagonist of the C-C Chemokine Receptor 6 (CCR6), effectively blocking CCR6-mediated chemotaxis with an IC50 of 5.7 nM in vitro. As a target of G protein-coupled receptors (GPCRs), PF-07054894 demonstrates significant potential in the study of inflammatory bowel disease and related immunological disorders, providing a valuable tool for understanding CCR6’s role in inflammation. -
CCR4 Antagonist
C-021 is a potent antagonist of the CC chemokine receptor-4 (CCR4). It effectively inhibits functional chemotaxis in both human and mouse models, exhibiting IC50 values of 140 nM and 39 nM, respectively. Additionally, C-021 demonstrates strong efficacy in blocking the binding of human CCL22-derived [35S]GTPγS to CCR4, with an IC50 of 18 nM. This compound is valuable for research applications focused on immune response modulation and cancer biology. -
CCR10 Antagonist
BI-6901 is a potent and selective antagonist of the CCR10 receptor, exhibiting a pIC50 of 9.0. It demonstrates high selectivity among various GPCRs, including multiple chemokine receptors. BI-6901 has shown efficacy in the murine DNFB model of contact hypersensitivity, making it a valuable tool in inflammation research. -
CCR Antagonist
INCB 3284 is a selective and potent antagonist of the human CCR2 receptor, functioning by inhibiting the binding of monocyte chemoattractant protein-1 to hCCR2, with an IC50 value of 3.7 nM. This compound is of particular interest in studies related to acute liver failure, providing insights into the role of CCR2 signaling in inflammatory processes. Its oral bioavailability makes it a valuable tool for in vivo research applications. -
CCR4 Antagonist
Tivumecirnon is a selective CCR4 antagonist that functions by blocking the interaction of CCR4 with its ligands, CCL17 and CCL22. This mechanism reduces the infiltration of regulatory T cells (Tregs) into the tumor microenvironment, thereby enhancing antitumor activity. It is useful for research applications aimed at understanding immune modulation in cancer therapy. -
CCR2b Antagonist
CCR2 antagonist 4 hydrochloride is a selective antagonist targeting the CCR2b receptor, exhibiting a potent inhibitory effect with an IC50 value of 180 nM. This compound effectively reduces MCP-1-induced chemotaxis, with an IC50 of 24 nM, making it a valuable tool for studying inflammatory pathways. Its application in research includes investigations into immune responses and the role of CCR2 in various disease models, particularly those related to monocyte migration and chronic inflammation. -
CCR Inhibitor
Ilacirnon is a potent CCR2 antagonist that specifically targets the C-C chemokine receptor type 2 (CCR2). This compound exhibits significant inhibitory activity, making it valuable in research focused on inflammatory diseases and immune response modulation. Ilacirnon can be utilized in studies exploring the role of CCR2 in various pathophysiological conditions, including atherosclerosis and chronic kidney disease. -
CCR1 Antagonist
AZD-4818 is a potent, orally active antagonist of the chemokine receptor CCR1. This compound selectively inhibits CCR1 signaling, making it a valuable tool for studying the role of this receptor in various inflammatory conditions. Applications include research into chronic obstructive pulmonary disease (COPD) and other related respiratory disorders. -
CCR2 Antagonist
BMS CCR2 22 is a potent antagonist of CC-type chemokine receptor 2 (CCR2), exhibiting a high binding affinity with an IC50 value of 5.1 nM. This compound demonstrates strong functional antagonism, as evidenced by its calcium flux IC50 of 18 nM and chemotaxis IC50 of 1 nM. BMS CCR2 22 is valuable for research applications targeting inflammatory responses and immune cell trafficking, providing insights into CCR2-related pathways. -
CCR Antagonist
MK-0812 Succinate is a potent and selective antagonist of the CCR2 receptor. It demonstrates high affinity for CCR2 and effectively inhibits its signaling pathway, making it a valuable tool for research into inflammatory and immune response processes. This compound is particularly relevant for studies focused on chronic pain, cardiovascular diseases, and various inflammatory disorders. -
CCR9 Antagonist
Vercirnon sodium is a potent and selective antagonist of CCR9, acting primarily by inhibiting CCR9-mediated Ca2+ mobilization and chemotaxis. This compound demonstrates significant biological activity, exhibiting IC50 values of 5.4 nM for Ca2+ mobilization and 3.4 nM for chemotaxis in Molt-4 cells. Vercirnon sodium shows high selectivity for CCR9, with IC50 values greater than 10 μM for other CCR and CX3CR subtypes. It effectively inhibits CCL25-directed chemotaxis in both CCR9 splice forms, CCR9A and CCR9B, with IC50 values of 2.8 nM and 2.6 nM, respectively, making it a valuable tool for research in inflammatory responses and related pathways. -
CCR4 Antagonist
CCR4 Antagonist 4 is a selective and potent inhibitor of the CC chemokine receptor-4 (CCR4), exhibiting an IC50 of 0.02 μM. This compound effectively blocks MDC-mediated chemotaxis and Ca2+ mobilization, with IC50 values of 0.007 μM and 0.003 μM, respectively. CCR4 Antagonist 4 is valuable for investigations into allergic inflammation mechanisms and related therapeutic applications. -
CCR8 Antagonist
CCR8 antagonist 1 is a potent antagonist of human CCR8, exhibiting an inhibition constant (Ki) of 1.6 nM. This compound demonstrates high safety and metabolic stability, making it suitable for in vitro and in vivo studies. CCR8 antagonist 1 is valuable for researching conditions such as asthma and multiple sclerosis, where CCR8-mediated pathways play a significant role in disease progression. -
CCR2 Negative Allosteric Modulator
AZD2423 functions as a negative allosteric modulator of the CCR2 chemokine receptor, exhibiting potent selectivity and oral bioavailability. With an IC50 value of 1.2 nM for CCR2-mediated Ca2+ flux, this compound is valuable for investigating the role of CCR2 in various physiological and pathological processes. AZD2423 is useful in research applications related to inflammation, cancer, and immune system modulation. -
CCR Antagonist
CCX354 is a CCR1 antagonist that primarily functions by inhibiting the receptor's signaling pathways, leading to a reduction in inflammatory responses. This compound demonstrates significant anti-inflammatory activity, making it a valuable tool for research into inflammatory diseases and conditions where CCR1-mediated signaling is implicated. Researchers can utilize CCX354 to explore mechanisms of inflammation and potential therapeutic strategies targeting CCR1. -
CCR1 Antagonist
CCR1 antagonist 9 is a potent and selective antagonist of the CCR1 receptor, exhibiting an IC50 of 6.8 nM in calcium flux assays. This compound plays a significant role in research related to inflammatory responses and immune system modulation. CCR1 antagonist 9 is valuable in studying the impact of CCR1 inhibition in various disease models including autoimmune and chronic inflammatory conditions. -
CCR1 Antagonist
BMS-817399 is a selective CCR1 antagonist that demonstrates high potency with a binding affinity IC50 of 1 nM and chemotaxis inhibition at 6 nM. This compound is orally bioavailable, making it suitable for in vivo studies. BMS-817399 is primarily utilized in research related to rheumatoid arthritis, providing insights into the modulation of inflammatory responses mediated by CCR1. -
CCR Antagonist
CCR3 Antagonist 1 is a potent antagonist of the CCR3 receptor, which plays a critical role in the pathogenesis of immunologic and inflammatory diseases. This compound is instrumental in studying the modulation of immune responses and the development of therapeutic strategies targeting CCR3-mediated signaling pathways. Its application is pivotal for researchers investigating conditions such as asthma, allergic responses, and other related disorders. -
CCR3 Inhibitor
ALK4290 is a potent, orally active inhibitor of CCR3, exhibiting a Ki of 3.2 nM for human CCR3. Its biological activity positions ALK4290 as a valuable tool for research into neovascular age-related macular degeneration and Parkinsonism. This compound may help elucidate the role of CCR3 in these diseases, facilitating the development of targeted therapeutic strategies. -
CCR9 Antagonist
MLN3126 is a potent CCR9 antagonist that exhibits significant oral bioavailability. It effectively inhibits CCL25-induced calcium mobilization and the chemotaxis of mouse primary thymocytes, demonstrating an IC50 value of 6.3 nM for calcium influx. This compound is valuable for research applications investigating immune cell trafficking and related pathways in inflammatory conditions.
